HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PCI 34051

an HDAC8 inhibitor

Also Known As:

PCI-34051; PCI-34058; PCI34051

Networked: 22 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Hydroxylamines: 16
    - Hydroxamic Acids: 239
      - PCI 34051: 22
- Carboxylic Acids: 973
  - Hydroxy Acids: 94
    - Hydroxamic Acids: 239
      - PCI 34051: 22
Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - PCI 34051: 22

Experts

1.	Jeong, Myung Ho: 3 articles (01/2022 - 01/2019)
2.	Kee, Hae Jin: 3 articles (01/2022 - 01/2019)
3.	Kee, Seung-Jung: 2 articles (01/2022 - 01/2021)
4.	Zhao, Tingwei: 2 articles (01/2022 - 01/2021)
5.	Oehme, Ina: 2 articles (01/2020 - 12/2018)
6.	Witt, Olaf: 2 articles (01/2020 - 12/2018)
7.	Huang, Wei-Jan: 2 articles (04/2016 - 10/2012)
8.	Bernardini, Giovanni: 1 article (11/2021)
9.	Cocozza, Germana: 1 article (11/2021)
10.	Esposito, Vincenzo: 1 article (11/2021)

Related Diseases

1.	Inflammation (Inflammations) 01/01/2022 - "PCI34051 treatment or Hdac8 knockdown alleviated inflammation as evidenced by Rela downregulation and Nfkbia upregulation in mice, as well as in cardiomyocytes, but not in cardiac fibroblasts. " 01/01/2019 - "PCI34051 lowered high blood pressure through modulation of arterial remodeling, vasoconstriction, and inflammation in an angiotensin II-induced hypertension model. " 12/01/2023 - "Curcumin and PCI-34051 combined treatment ameliorates inflammation and fibrosis by affecting MAP kinase pathway." 12/01/2016 - "Administration of PCI-34051 and dexamethasone reduced the eosinophilic inflammation and airway hyperresponsiveness in asthma to reduce the airway remodeling. "
2.	Fibrosis (Cirrhosis) 01/01/2022 - "Moreover, PCI34051 or Hdac8 knockdown in rat cardiac fibroblasts alleviated cardiac fibrosis through the Tgfb1-Smad2/3 pathway. " 01/01/2022 - "Picrosirius red staining, real-time polymerase chain reaction, and western blotting analyses revealed that PCI34051 alleviated fibrosis and downregulated fibrosis-related genes. " 12/01/2023 - "Curcumin and PCI-34051 combined treatment ameliorates inflammation and fibrosis by affecting MAP kinase pathway." 01/01/2021 - "PCI34051 treatment also reduced the expression of cardiac hypertrophic markers (Nppa, Nppb, and Myh7), transcription factors (Sp1, Gata4, and Gata6), and fibrosis markers (collagen type I, fibronectin, and Ctgf) in isoproterenol-treated mice. "
3.	T-Cell Lymphoma (Lymphoma, T Cell) 10/05/2023 - "A specific HDAC8 inhibitor PCI-34051 showed promising results against both T-cell lymphoma and AML. " 05/01/2008 - "A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas." 05/01/2008 - "PCI-34051 induces caspase-dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias, but not in other hematopoietic or solid tumor lines. "
4.	Hypertension (High Blood Pressure) 01/01/2019 - "The purpose of this study was to investigate whether PCI34051, an HDAC8-selective inhibitor, can modulate angiotensin II-induced hypertension and its regulatory mechanism. " 01/01/2019 - "PCI34051 lowered high blood pressure through modulation of arterial remodeling, vasoconstriction, and inflammation in an angiotensin II-induced hypertension model. "
5.	Neuroblastoma 01/01/2020 - "The best substance inhibited the viability of the SK-N-BE(2)C neuroblastoma cell line with an IC50 value similar to a combination treatment with Tubastatin A and PCI-34051. " 08/10/2017 - "The cytotoxicity of 3g and 3n was evaluated in neuroblastoma cell lines, and 3n displayed concentration-dependent cytotoxicity similar to or better than that of PCI-34051. " 12/01/2018 - "Accordingly, the combination of the ALK/MET inhibitor crizotinib and selective HDAC8 inhibitors (3-6 µM PCI-34051 or 10 µM 20a) efficiently killed neuroblastoma cell lines carrying wildtype ALK (SK-N-BE(2)-C, IMR5/75), amplified ALK (NB-1), and those carrying the activating ALK F1174L mutation (Kelly), and, in cells carrying the activating R1275Q mutation (LAN-5), combination treatment decreased viable cell count. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Curcumin
3.	Angiotensin II
4.	Histone Deacetylase Inhibitors
5.	Therapeutic Uses
6.	Messenger RNA (mRNA)
7.	Catenins
8.	Collagen Type I (Type I Collagen)
9.	Protein Isoforms (Isoforms)
10.	Dialysis Solutions

Related Therapies and Procedures

1.	Therapeutics
2.	Peritoneal Dialysis